BioVaria 2025

BioVaria 2025

ABOUT BIOVARIA

BioVaria targets technology scouts, business developers and investors highlighting commercially attractive licensing opportunities and promising startups from across Europe.

This unique event brings together Europe‘s leading tech transfer professionals, innovators from academia and start-ups with investors and representatives of the global biotech and pharma industry.

//

  • Scientists, technology transfer professionals, investors and industry scouts
  • European technology transfer organizations presenting commercially attractive licensable technologies and partnership opportunities
  • Startup Pitch & Partner featuring some of Europe’s most promising startups
  • Face-to-face discussions with investors and inventors

STARTUP PITCH & PARTNER

The interactive BioVaria Startup Pitch & Partner Programme offers start-ups from all life-science areas (pharma, diagnostics, medtech and digital health)

  • the possibility to present their technology and business concept
  • direct exchange with potential VCs and investors during speed dating
  • the opportunity to network with representatives of the industry and the life science scene

Applications are open to pre- and post-seed start-ups. Start-ups selected by an expert jury of investors will then compete live on the BioVaria stage for a “BioVaria Startup Award” worth up to 2,000 euros.

The application deadline for start-ups is February 14, 2025.

The application form can be found on our website: https://www.biovaria.org/startup-pitch-partner/startup-pitch-partner

register now

Our latest News

discover more
Green hydrogen for a climate-neutral industry: InnovationLab organizes Clean Tech Innovation Day

Green hydrogen for a climate-neutral industry: InnovationLab organizes Clean Tech Innovation Day

Heidelberg, Germany, November 6, 2024 – The technology transfer platform InnovationLab is looking forward to the premiere of a new event format: hydrogen experts from Germany and abroad are expected to attend the Clean Tech Innovation Day on Monday, November 11 (9 a.m. to 6 p.m.). Together with its two co-partners, the Rhine-Neckar metropolitan region […]

New findings on cell types and their interactions in multiple sclerosis

New findings on cell types and their interactions in multiple sclerosis

An international research team led by Professor Dr. Lucas Schirmer and Professor Dr. Julio Saez-Rodriguez from the Medical Faculties of Heidelberg University, in Mannheim and Heidelberg, has studied the different cell types in so-called subcortical lesions, tissue damage to deep brain structures, at different stages of multiple sclerosis (MS) and investigated how they communicate. In […]

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics

Partnership to Combine AbbVie’s Oncology Expertise with EvolveImmune’s Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current immunotherapies, today announced a collaboration […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp